High availability across all drug types, drug production within Europe and highly potent substances are among the concerns addressed today by the (EMCDDA in its European Drug Report 2020: Trends and Developments. In its latest annual review — marking 25 years of monitoring — the agency describes the drug situation at the end of 2019, along with recent changes brought by the COVID-19 pandemic in early 2020.
This video presents the key issues of the report.